NOUVEAUX DERIVES DE BENZO[B]PYRANO[3,2-H]ACRIDIN-7-ONE, LEURPROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

    公开(公告)号:CA2395652C

    公开(公告)日:2008-12-30

    申请号:CA2395652

    申请日:2002-07-25

    Applicant: SERVIER LAB

    Abstract: L'invention concerne de nouveaux composés répondant à la formule (I) (See formula I) dans laquelle X et Y, identiques ou différents, représentent chacun un atome d'hydrogène ou d'halogène, ou un groupement mercapto, cyano, nitro, alkyle, trihalogénoalkyle ou trihalogénoalkylcarbonylamino, ou un groupement de formule ORa, NRaRb, -NRa- C(O)- T1, -O-C(O)-T1, -O-T2-NRaRb, -O-T2-ORa, -NRa-T2-NRaRb, -NRa-T2-ORa ou -NRa-T 2- CO2Ra dans lesquels Ra représente un atonie d'hydrogène ou un groupement alkyle, aryle ou arylalkyle, Rb représente un atome d'hydrogène ou un groupement alkyle, aryle ou arylalkyle, ou Ra et Rb forment ensemble avec l'atome d'azote qui les porten t un hétérocycle de 5 à 6 chaînons, T1 représente un groupement alkyle, alkényle, aryle ou arylalkyle ou une chaîne alkylène substituée par un groupement -ORa ou -NRaR b dans lesquels Ra et Rb sont tels que définis précédemment, T2 représente une chaî ne alkylène, ou X et Y, lorsqu'ils sont en positions adjacentes, forment ensemble un groupement méthylènedioxy ou éthylènedioxy; R1 représente un atome d'hydrogène ou un groupement alkyle; R2 représente un atome d'hydrogène, un groupement alkyle ou un groupement ORa, NRaRb, -NRa-C(O)-T1, -O-C(O)-T1, -O-T2-NRaRb, -O-T2-ORa, -NRa-T2-NRaRb, -NRa - T2-ORa ou -NRa-T2-CO2Ra dans lesquelsRa, Rb, T1 et T2, sont tels que définis précédemment; R3 et R4, identiques ou différents, représentent un atome d'hydrogène ou un groupement alkyle; W représente un groupement de formule -CH(R5)-CH(R6)-, -CH=C(R7)-, -C(R7)=CH- ou -C(O)-CH(R8)- dans lesquelles R5 et R6, identiques ou différents, représentent un groupement -W1-C(W2)-W3-T'1, -W4-C(W2)-T'1, -W1- S(O)n-W3- T1 ou -W1-S(O)n-T1 dans lesquels W1 représente un atome d'oxygène, de soufre ou un atome d'azote substitué, W2 représente un atome d'oxygène ou un atome de soufre, W3 représente un atome d'oxygène, de soufre ou un atome d'azote substitué, ou u ne liaison lorsque T1 représente un groupement alkényle, W4 représente un atome de souf re ou un atome d'azote substitué, T1 est tel que défini précédemment, T'1 représente un groupement alkényle ou arylalkyle, ou une chaîne alkylène substituée par un groupement - ORa ou - NRaRb dans lesquels Ra et Rb sont tels que définis précédemment, n représent e 1 ou 2, et dans le cas où un seul des deux groupements R5 et R6 représente un groupemen t tel que défini précédemment, alors l'autre desdits groupements R5 ou R6 représente u n atome d'hydrogène ou un groupement hydroxy, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, arylalkylcarbonyloxy ou amino éventuellement substitué, R7 représente un groupement hydroxy ou groupement alkoxy, ou un groupement -C(W2)-T1, -W1-C(W2)-W3-T1, - W1- C(W2)-T1, -W1-S(O)n-W3-T1 ou -W1-S(O)n-T1 dans lesquels W1, W2, W3, T1 et n sont tels que définis précédemment, R8 représente un groupement alkoxy ou alkylcarbonyloxy. L'invention vise également les énantiomères, diastéréoisomères et N-oxydes composés de formule (I), ainsi que leurs sels d'addition à un acide ou à une base pharmaceutiquement acceptable. Les composés selon l'invention sont utiles à titre de médicament s pour le traitement de cancers.

    DERIVADOS DE BENZO(B)PIRANO(3,2-H)ACRIDIN-7-ONA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.

    公开(公告)号:ES2294090T3

    公开(公告)日:2008-04-01

    申请号:ES02291862

    申请日:2002-07-24

    Applicant: SERVIER LAB

    Abstract: Compuestos de fórmula (I): (Ver fórmula) donde: ¿ X e Y, idénticos o diferentes, independientemente uno del otro, representan cada uno un grupo seleccionado entre: - un átomo de hidrógeno, halógeno, - un grupo mercapto, ciano, nitro, alquilo(C1-C6) lineal o ramificado, trihaloalquilo(C1-C6) lineal o ramificado, trihaloalquilcarbonilamino (C1-C6) lineal o ramificado, - un grupo de fórmulas ORa, NRaRb, -NRa-C(O)-T1, -O-C(O)-T1, -O-T2-NRaRb, -O-T2-ORa, -NRa-T2-NRaRb, -NRa-T2-ORa y -NRa-T2-CO2Ra, en las cuales: * Ra representa un grupo seleccionado de entre un átomo de hidrógeno, un grupo alquilo(C1-C6) lineal o ramificado, arilo, y arilalquilo(C1-C6) lineal o ramificado, * Rb representa un grupo seleccionado de entre un átomo de hidrógeno, un grupo alquilo(C1-C6) lineal o ramificado, arilo, y arilalquilo(C1-C6) lineal o ramificado, ó Ra+Rb forman, junto con el átomo de nitrógeno que los porta, un heterociclo de 5 a 6 eslabones, monocíclico, conteniendo eventualmente en el seno del sistema cíclico un segundo heteroátomo seleccionado de entre oxígeno y nitrógeno, * T1 representa un grupo seleccionado entre alquilo(C1-C6)lineal o ramificado, alquenilo(C2-C6) lineal o ramificado, arilo, arilalquilo(C1-C6) lineal o ramificado y una cadena alquileno(C1-C6) lineal o ramificada sustituida con un grupo seleccionado entre -ORa y -NRaRb, siendo Ra y Rb tal como se han definido anteriormente, * T2 representa una cadena alquileno(C1-C6) lineal o ramificada, - ó X e Y, cuando se encuentran en posiciones adyacentes, forman juntos un grupo metilendioxi o un grupo etilendioxi, entendiéndose que los sustituyentes X e Y pueden estar presentes en uno u otro de los dos ciclos bencénicos adyacentes, ¿ R1 representa...

    4.
    发明专利
    未知

    公开(公告)号:NO20056091L

    公开(公告)日:2006-06-23

    申请号:NO20056091

    申请日:2005-12-21

    Applicant: SERVIER LAB

    Abstract: Benzo pyarano[3,2-h]acridin-7-one cinnamate compounds (I) and their enantiomers, diastereoisomers, hydrates, solvates, acids, bases or addition salts are new. Benzo pyarano[3,2-h]acridin-7-one cinnamate compounds of formula (I) and their enantiomers, diastereoisomers, hydrates, solvates, acids, bases or addition salts are new. X, Y 1H, halo, OH, (1-6C) alkoxy, nitro, CN, (1-6C) alkyl (optionally substituted by one or more OH or halo), (2-6C) alkenyl or -NRaRb; either R-a, R-b : H or (1-6C) alkyl; or N-R-aR-b : a monocyclic or 5-7-membered heterocycle optionally having a second heteroatom of O or N in the cyclic system; Z : O or NR-c; R-c : H, (1-6C) alkyl, aryl or aryl-(1-6C)alkyl; Ar : (hetero)aryl; R 1, R 3, R 4H or (1-6C) alkyl; R 2H, (1-6C) alkyl, OR-a or NR-aR-b; R 5OR-c, NR-cR-d, W 1-C(W 2)-U 1-V 1, W-a-C(W 2)-W 3-T 1 or -Z-CO-CH=CHAr; W-a, W 3O or NR-c; W 2O; U 1(1-8C) alkylene or (2-8C) alkenylene; V 1H, (hetero) aryl, OR, CO 2R-c, COR-c, CON-aaR-bb, NR-aaR-bb, N(R-c)-CO 2R-cc or N(R-c)COR-cc; R-cc : R-c; either R-aa, R-bb : R-a, R-b or aryl-(1-6C)alkyl; or N-R-aaR-bb : N-R-aR-b; and T 1H, (1-6C) alkyl or (2-6C) alkenyl, aryl or aryl-(1-6C) alkyl (all optionally substituted by OR-c or NR-aaR-bb). where the aryl is phenyl or naphthyl optionally substituted by one or more substituents of (1-6C) alkyl (optionally substituted by one or more OH or halo), OH, halo, carboxy, NO 2, NH 2, or mono- or di-(1-6C) alkylamino, where the alkyl moiety is (1-6C) alkoxy, (1-6C) acyl or (1-6C) alkylcarbonyloxy; and the heteroaryl is 5-12-membered (monocyclic, aromatic or bicyclic with aromatic ring(s)), and has 1, 2 or 3 heteroatoms of O, N or S, and optionally substituted by one or more groups of halo, (1-6C) alkyl optionally substituted by one or more OH, halo, (1-6C) alkoxy or NH 2 optionally substituted by one or two (1-6C)alkyl. [Image] ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given.

    8.
    发明专利
    未知

    公开(公告)号:BRPI0500306A

    公开(公告)日:2005-09-27

    申请号:BRPI0500306

    申请日:2005-02-03

    Applicant: SERVIER LAB

    Abstract: Benzo[b]chromeno[g]naphthyridone or pyrano[2',3':7,8]quinolino[2,3-b]quinoxalinone derivatives (I) are new. Benzo[b]chromeno[g]naphthyridone or pyrano[2',3':7,8]quinolino[2,3-b]quinoxalinone derivatives of formula (I) and their isomers, N-oxides and salts are new: B 1, B 2C or N, at least one being N; X, Y : H, halo, OH, 1-6C alkoxy, NO 2, CN, 1-6C alkyl, 2-6C alkenyl, 1-6C polyhaloalkyl or NR aR b; R a, R bH, COCF 3, CONH 2 or 1-6C alkyl optionally substituted with NR' aR' b or NR aR b is a 5- to 7-membered ring optionally containing another heteroatom (O or N); R' a, R' bH or 1-6C alkyl, or NR' aR' b is a 5- to 7-membered ring optionally containing another heteroatom (O or N); X 1, Y 1X and Y or are absent when B 1, B 2 is N; R 1H or 1-6C alkyl; R 2H, 1-6C alkyl, OR" a, NR' aR' b, OT aOR" a, NR" aT aNR' aR' b, NR" aCOT aH, OCOT aH, OT aNR' aR' b, NR" aT aOR" a, NR" aT aCOOR" a or NR" aCOT aNR' aR' b; T a1-6C alkylene; R" aH or 1-6C alkyl; R 3, R 4H or 1-6C alkyl or together form a 3- to 6-membered ring; A : CHR 5CHR 6, CH=CR 7, CR 7=CH, COCHR 8 or CHR 8CO; R 5, R 6H, OR c, NR cR d, SR c, W 1C(W 2)U'V', W 1C(W 2)W 3T 1, W 1SO nW 3T 1, W 1SO nT 1 or C(W 2)T 1, or together form OC(Z)O, NHC(Z)O, OC(Z)NH, NHC(Z)NH, O(CH 2) mO, OCOB'COO, NHCOB'COO or OCOB'CONH, or CR 5R 6 is an oxirane or optionally N-substituted aziridine group; R c, R dH, 1-6C alkyl, aryl, aryl(1-6C)alkyl or COR e; R eH, aryl or NR"' aR"' b; R"' a, R"' bH or NR"' aR"' b is a 5- to 7-membered ring optionally containing another heteroatom (O or N); W 1O, S or NR c; W 2O or S; U' : 1-8C alkylene or 2-8C alkenylene, or is a bond when W 2 is not O and V' is not H, aryl or NH 2; V' : H, aryl, OR c, COOR c, COR c, CONR' aR' b, NR cR d, N(R c)COOR' c or N(R c)COR' c; R' c1-6C alkyl, aryl or aryl(1-6C)alkyl; W 3O, S or NR c; T 1H, 1-6C alkyl, 2-6C alkenyl, aryl, aryl(1-6C)alkyl, or 1-6C alkyl or 2-6C alkenyl substituted with OR c or NR' aR' b; n : 1 or 2; Z : O or S; m : 1-4; B' : bond, 1-6C alkylene or 2-6C alkenylene; R 7H, OR" a, W 1C(W 2)U'V', W 1C(W 2)W 3T 1, W 1SO nW 3T 1, W 1SO nT 1 or C(W 2)T 1; and R 8H, 2-7C alkanoyloxy or OR" a. An independent claim is also included for the preparation of (I). [Image] ACTIVITY : Cytostatic. cis-1,2-Acetoxy-6-methoxy-3,3,14-trimethyl-1,2,3,14-tetrahydro-7H-benzo[b]chromeno[6,5-g][1,8]naphthyridin-7-one had IC50 values of 0.32 mu M against L1210 murine leukemia cells and 0.037 mu M against KB-3-1 human epidermoid carcinoma cells. MECHANISM OF ACTION : Cell cycle blocker.

    BenzoÄBÜchromeno-naphthyridin-7-one and pyranoÄ2'3':7,8ÜquinoÄ2,3-BÜquinoxalin-7-one compounds, process for their preparation and pharmaceutical compositions containing them.

    公开(公告)号:ZA200501010B

    公开(公告)日:2005-08-30

    申请号:ZA200501010

    申请日:2005-02-03

    Applicant: SERVIER LAB

    Abstract: Benzo[b]chromeno[g]naphthyridone or pyrano[2',3':7,8]quinolino[2,3-b]quinoxalinone derivatives (I) are new. Benzo[b]chromeno[g]naphthyridone or pyrano[2',3':7,8]quinolino[2,3-b]quinoxalinone derivatives of formula (I) and their isomers, N-oxides and salts are new: B 1, B 2C or N, at least one being N; X, Y : H, halo, OH, 1-6C alkoxy, NO 2, CN, 1-6C alkyl, 2-6C alkenyl, 1-6C polyhaloalkyl or NR aR b; R a, R bH, COCF 3, CONH 2 or 1-6C alkyl optionally substituted with NR' aR' b or NR aR b is a 5- to 7-membered ring optionally containing another heteroatom (O or N); R' a, R' bH or 1-6C alkyl, or NR' aR' b is a 5- to 7-membered ring optionally containing another heteroatom (O or N); X 1, Y 1X and Y or are absent when B 1, B 2 is N; R 1H or 1-6C alkyl; R 2H, 1-6C alkyl, OR" a, NR' aR' b, OT aOR" a, NR" aT aNR' aR' b, NR" aCOT aH, OCOT aH, OT aNR' aR' b, NR" aT aOR" a, NR" aT aCOOR" a or NR" aCOT aNR' aR' b; T a1-6C alkylene; R" aH or 1-6C alkyl; R 3, R 4H or 1-6C alkyl or together form a 3- to 6-membered ring; A : CHR 5CHR 6, CH=CR 7, CR 7=CH, COCHR 8 or CHR 8CO; R 5, R 6H, OR c, NR cR d, SR c, W 1C(W 2)U'V', W 1C(W 2)W 3T 1, W 1SO nW 3T 1, W 1SO nT 1 or C(W 2)T 1, or together form OC(Z)O, NHC(Z)O, OC(Z)NH, NHC(Z)NH, O(CH 2) mO, OCOB'COO, NHCOB'COO or OCOB'CONH, or CR 5R 6 is an oxirane or optionally N-substituted aziridine group; R c, R dH, 1-6C alkyl, aryl, aryl(1-6C)alkyl or COR e; R eH, aryl or NR"' aR"' b; R"' a, R"' bH or NR"' aR"' b is a 5- to 7-membered ring optionally containing another heteroatom (O or N); W 1O, S or NR c; W 2O or S; U' : 1-8C alkylene or 2-8C alkenylene, or is a bond when W 2 is not O and V' is not H, aryl or NH 2; V' : H, aryl, OR c, COOR c, COR c, CONR' aR' b, NR cR d, N(R c)COOR' c or N(R c)COR' c; R' c1-6C alkyl, aryl or aryl(1-6C)alkyl; W 3O, S or NR c; T 1H, 1-6C alkyl, 2-6C alkenyl, aryl, aryl(1-6C)alkyl, or 1-6C alkyl or 2-6C alkenyl substituted with OR c or NR' aR' b; n : 1 or 2; Z : O or S; m : 1-4; B' : bond, 1-6C alkylene or 2-6C alkenylene; R 7H, OR" a, W 1C(W 2)U'V', W 1C(W 2)W 3T 1, W 1SO nW 3T 1, W 1SO nT 1 or C(W 2)T 1; and R 8H, 2-7C alkanoyloxy or OR" a. An independent claim is also included for the preparation of (I). [Image] ACTIVITY : Cytostatic. cis-1,2-Acetoxy-6-methoxy-3,3,14-trimethyl-1,2,3,14-tetrahydro-7H-benzo[b]chromeno[6,5-g][1,8]naphthyridin-7-one had IC50 values of 0.32 mu M against L1210 murine leukemia cells and 0.037 mu M against KB-3-1 human epidermoid carcinoma cells. MECHANISM OF ACTION : Cell cycle blocker.

    10.
    发明专利
    未知

    公开(公告)号:FR2865734A1

    公开(公告)日:2005-08-05

    申请号:FR0400988

    申请日:2004-02-03

    Applicant: SERVIER LAB

    Abstract: Benzo[b]chromeno[g]naphthyridone or pyrano[2',3':7,8]quinolino[2,3-b]quinoxalinone derivatives (I) are new. Benzo[b]chromeno[g]naphthyridone or pyrano[2',3':7,8]quinolino[2,3-b]quinoxalinone derivatives of formula (I) and their isomers, N-oxides and salts are new: B 1, B 2C or N, at least one being N; X, Y : H, halo, OH, 1-6C alkoxy, NO 2, CN, 1-6C alkyl, 2-6C alkenyl, 1-6C polyhaloalkyl or NR aR b; R a, R bH, COCF 3, CONH 2 or 1-6C alkyl optionally substituted with NR' aR' b or NR aR b is a 5- to 7-membered ring optionally containing another heteroatom (O or N); R' a, R' bH or 1-6C alkyl, or NR' aR' b is a 5- to 7-membered ring optionally containing another heteroatom (O or N); X 1, Y 1X and Y or are absent when B 1, B 2 is N; R 1H or 1-6C alkyl; R 2H, 1-6C alkyl, OR" a, NR' aR' b, OT aOR" a, NR" aT aNR' aR' b, NR" aCOT aH, OCOT aH, OT aNR' aR' b, NR" aT aOR" a, NR" aT aCOOR" a or NR" aCOT aNR' aR' b; T a1-6C alkylene; R" aH or 1-6C alkyl; R 3, R 4H or 1-6C alkyl or together form a 3- to 6-membered ring; A : CHR 5CHR 6, CH=CR 7, CR 7=CH, COCHR 8 or CHR 8CO; R 5, R 6H, OR c, NR cR d, SR c, W 1C(W 2)U'V', W 1C(W 2)W 3T 1, W 1SO nW 3T 1, W 1SO nT 1 or C(W 2)T 1, or together form OC(Z)O, NHC(Z)O, OC(Z)NH, NHC(Z)NH, O(CH 2) mO, OCOB'COO, NHCOB'COO or OCOB'CONH, or CR 5R 6 is an oxirane or optionally N-substituted aziridine group; R c, R dH, 1-6C alkyl, aryl, aryl(1-6C)alkyl or COR e; R eH, aryl or NR"' aR"' b; R"' a, R"' bH or NR"' aR"' b is a 5- to 7-membered ring optionally containing another heteroatom (O or N); W 1O, S or NR c; W 2O or S; U' : 1-8C alkylene or 2-8C alkenylene, or is a bond when W 2 is not O and V' is not H, aryl or NH 2; V' : H, aryl, OR c, COOR c, COR c, CONR' aR' b, NR cR d, N(R c)COOR' c or N(R c)COR' c; R' c1-6C alkyl, aryl or aryl(1-6C)alkyl; W 3O, S or NR c; T 1H, 1-6C alkyl, 2-6C alkenyl, aryl, aryl(1-6C)alkyl, or 1-6C alkyl or 2-6C alkenyl substituted with OR c or NR' aR' b; n : 1 or 2; Z : O or S; m : 1-4; B' : bond, 1-6C alkylene or 2-6C alkenylene; R 7H, OR" a, W 1C(W 2)U'V', W 1C(W 2)W 3T 1, W 1SO nW 3T 1, W 1SO nT 1 or C(W 2)T 1; and R 8H, 2-7C alkanoyloxy or OR" a. An independent claim is also included for the preparation of (I). [Image] ACTIVITY : Cytostatic. cis-1,2-Acetoxy-6-methoxy-3,3,14-trimethyl-1,2,3,14-tetrahydro-7H-benzo[b]chromeno[6,5-g][1,8]naphthyridin-7-one had IC50 values of 0.32 mu M against L1210 murine leukemia cells and 0.037 mu M against KB-3-1 human epidermoid carcinoma cells. MECHANISM OF ACTION : Cell cycle blocker.

Patent Agency Ranking